Journal of dental sciences · 2026
2-O-Methylmagnolol suppresses oral squamous cell carcinoma progression by targeting c-MYC signaling.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Chi-Yuan, Shieh Tzong-Ming, Chen Chin-Chuan, Leu Yann-Lii, Chu Yu-De, Liou Miaw-Jene, Liu Yi-Tsen, Lin Hsin-Wei, Chen Kai-Yin, Yu Cheng-Chia, Wang Tong-Hong
Аннотация
BACKGROUND/PURPOSE: Oral squamous cell carcinoma (OSCC) is characterized by aggressive growth and frequent recurrence, highlighting the need for novel targeted therapies. Magnolol, a bioactive compound derived from Magnolia officinalis, exhibits anti-tumor activity. In this study, we synthesized a methoxylated derivative, 2-O-methylmagnolol (MM1), and evaluated the anti-OSCC efficacy and underlying mechanisms of magnolol and MM1.
MATERIALS AND METHODS: Human OSCC cell lines (SAS and OECM1) were treated with magnolol or MM1. Cell proliferation, migration, and invasion were analyzed using functional assays. Cell-cycle distribution and apoptosis were assessed by flow cytometry and DiOC6/PI staining. Protein expression of c-MYC and downstream regulators was examined by Western blotting. Anti-tumor efficacy was further evaluated in a xenograft mouse model.
RESULTS: Both magnolol and MM1 significantly inhibited OSCC cell proliferation, migration, and invasion, and induced G1-phase arrest and apoptosis. MM1 consistently demonstrated greater anti-tumor potency than magnolol. Mechanistically, both compounds downregulated c-MYC protein expression, accompanied by increased p21 and decreased CDC25A, CDK4, and Cyclin D1 levels, resulting in G1-S cell-cycle blockade. Epithelial-mesenchymal transition (EMT)-associated proteins were also suppressed, consistent with reduced migratory and invasive capacity. In vivo, MM1 produced stronger tumor growth inhibition without evident systemic toxicity.
CONCLUSION: MM1 suppresses OSCC progression through coordinated inhibition of c-MYC associated oncogenic pathways and represents a promising candidate for further preclinical development.
MATERIALS AND METHODS: Human OSCC cell lines (SAS and OECM1) were treated with magnolol or MM1. Cell proliferation, migration, and invasion were analyzed using functional assays. Cell-cycle distribution and apoptosis were assessed by flow cytometry and DiOC6/PI staining. Protein expression of c-MYC and downstream regulators was examined by Western blotting. Anti-tumor efficacy was further evaluated in a xenograft mouse model.
RESULTS: Both magnolol and MM1 significantly inhibited OSCC cell proliferation, migration, and invasion, and induced G1-phase arrest and apoptosis. MM1 consistently demonstrated greater anti-tumor potency than magnolol. Mechanistically, both compounds downregulated c-MYC protein expression, accompanied by increased p21 and decreased CDC25A, CDK4, and Cyclin D1 levels, resulting in G1-S cell-cycle blockade. Epithelial-mesenchymal transition (EMT)-associated proteins were also suppressed, consistent with reduced migratory and invasive capacity. In vivo, MM1 produced stronger tumor growth inhibition without evident systemic toxicity.
CONCLUSION: MM1 suppresses OSCC progression through coordinated inhibition of c-MYC associated oncogenic pathways and represents a promising candidate for further preclinical development.